Nebido Testosterone Undecanoate / for

Phase 2Small molecule

UUniversity Hospital, Strasbourg, France

Nebido Testosterone Undecanoate / for is one of 30 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Myfortic

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Multiple Sclerosis

NCT03910738

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 2·NCT03910738·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nebido Testosterone Undecanoate / for. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nebido Testosterone Undecanoate / for compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nebido Testosterone Undecanoate / for. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Strasbourg, France

Nebido Testosterone Undecanoate / for

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News